DTM™ spinal cord stimulation shows superior back pain relief in RCT
By Akshay Kedari  Date: 2020-01-22

DTM™ spinal cord stimulation shows superior back pain relief in RCT

Medtronic plc, a Dublin-based medical technology, services, and solutions company, has reportedly announced three-month results from a large, multicenter RCT (randomized controlled trial) demonstrating statistically meaningful (p=0.0009) and improved back pain relief with DTM (Differential Target Multiplexed) SCS (Spinal Cord Stimulation) compared to conventional SCS. Both arms have used the company’s Intellis™ platform.

Reportedly, the three-month outcomes demonstrated 80% of chronic back pain patients treated with DTM registered minimum 50% pain relief, compared to 51% of the patients treated with conventional SCS, as measured by VAS (Visual Analog Scale).

Meanwhile, the RCT showed great pain relief and substantial reductions in leg and back pain with DTM. 63% of patients with back pain treated with DTM showed great pain relief of 80% or more compared to 26% treated with conventional SCS.

All in all, patients treated with DTM demonstrated an average of 74% decrease in back pain compared to 46% with conventional SCS for three months period. Likewise, improvements were noted with DTM for leg pain with a mean decrease of 72% compared to 59% with conventional SCS.

Matt Thomas, General Manager and Vice President of the Stim and Early Interventions business, that is part of the Restorative Therapies Group at Medtronic, said that DTM therapy is the first customized SCS approach purposely created from new scientific concept and demonstrated in an RCT.

The clinical study determines that DTM therapy offers greater efficacy for chronic back pain patients compared to conventional stimulation. Moreover, when combined with Medtronic Intellis, patients could access superior results as displayed in the RCT on an unrivaled simulation platform.

For a record, Medtronic secured DTM therapy as part of its acquisition of Stimgenics declared in early January. DTM therapy is a new and unique programming option to treat patients who are suffering from chronic pain, and is based on years of preclinical research.

Source Credit - http://newsroom.medtronic.com/news-releases/news-release-details/dtmtm-spinal-cord-stimulation-using-medtronic-intellistm

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...

GVN adds EVIT Center and Chumakov as its new Centers of Excellence
GVN adds EVIT Center and Chumakov as its new Centers of Excellence
By Akshay Kedari

The Global Virus Network (GVN), an international coalition of medical virologists, has recently announced the addition of Australian and Russian researchers. GVN is adding the Center for EVIT (Emerging Viruses, Inflammation & Therapeutics) of th...

Wind Point Partners takes over RTIC to expand business portfolio
Wind Point Partners takes over RTIC to expand business portfolio
By Akshay Kedari

American private equity firm, Wind Point Partners has recently signed an acquisition deal with the one of the biggest direct-to-consumer (D2C) eCommerce providers of drinkware, RTIC. Reportedly, RTIC is Wind Point’s third acquisition of a famil...

Novartis reveals positive data from Phase III ORION trials of inclisiran
Novartis reveals positive data from Phase III ORION trials of inclisiran
By Akshay Kedari

Swiss multinational pharmaceutical firm, Novartis has recently announced results from its Phase III ORION-10 and -11 studies that focus on assessing the individual responses of patients on lowering low-density lipoprotein cholesterol (LDL-C) with inc...

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...